Naratriptan drug interactions: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Naratriptan}} {{CMG}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NARATRIPTAN TABLET, COATED [SANDOZ INC] | url = http://dailym...")
 
mNo edit summary
 
Line 3: Line 3:
{{CMG}}
{{CMG}}


==Drug Interactions==


======Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome======


Cases of life-threatening serotonin syndrome have been reported during combined use of SSRIs or SNRIs and triptans (see WARNINGS).


<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = NARATRIPTAN TABLET, COATED [SANDOZ INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39c658d3-5bc8-4f81-9837-1c4edcf1b6c2 | publisher =  | date =  | accessdate = }}</ref>
======Ergot-Containing Drugs======
 
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated (see CONTRAINDICATIONS).
 
======Other 5-HT1 Agonists======
 
The administration of naratriptan with other 5-HT1 agonists has not been evaluated in migraine patients. Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended (see CONTRAINDICATIONS).
 
======Drug/Laboratory Test Interactions======
 
Naratriptan tablets are not known to interfere with commonly employed clinical laboratory tests.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = NARATRIPTAN TABLET, COATED [SANDOZ INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39c658d3-5bc8-4f81-9837-1c4edcf1b6c2 | publisher =  | date =  | accessdate = }}</ref>


==References==
==References==

Latest revision as of 20:09, 3 February 2014

Naratriptan
NARATRIPTAN tablet® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Naratriptan
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Drug Interactions

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome

Cases of life-threatening serotonin syndrome have been reported during combined use of SSRIs or SNRIs and triptans (see WARNINGS).

Ergot-Containing Drugs

Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated (see CONTRAINDICATIONS).

Other 5-HT1 Agonists

The administration of naratriptan with other 5-HT1 agonists has not been evaluated in migraine patients. Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended (see CONTRAINDICATIONS).

Drug/Laboratory Test Interactions

Naratriptan tablets are not known to interfere with commonly employed clinical laboratory tests.[1]

References

  1. "NARATRIPTAN TABLET, COATED [SANDOZ INC]".

Adapted from the FDA Package Insert.

Template:Antimigraine preparations